CONCLUSION
ADVERSE EVENT, SOLID TUMORS
In this study of pemigatinib in Japanese patients with advanced solid tumors, no new safety signals were observed. Adverse events were typical of those seen with FGFR inhibition and were generally manageable. The safety, PK, and pharmacodynamic profiles of pemigatinib in Japanese patients with advanced solid tumors in this study are consistent with those observed previously in FIGHT‐101.